Oncolytics Biotech (ONCY) 20-F 5 Mar 21 2020 FY Annual report (foreign) Financial data

Cover

Cover	12 Months Ended
	Dec. 31, 2020shares
Cover [Abstract]
Entity Registrant Name	ONCOLYTICS BIOTECH INC
Entity Central Index Key	0001129928
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	20-F
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding	46,166,980
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

CONSOLIDATED STATEMENTS OF FINA

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	Dec. 31, 2020CAD ($)	Dec. 31, 2019CAD ($)
Current assets
Cash and cash equivalents	$ 31,219,574	$ 14,148,021
Other receivables	89,661	2,068,772
Prepaid expenses	2,427,200	2,713,591
Total current assets	33,736,435	18,930,384
Non-current assets
Property and equipment	236,664	296,768
Right-of-use assets	372,468	430,713
Total non-current assets	609,132	727,481
Total assets	34,345,567	19,657,865
Current Liabilities
Accounts payable and accrued liabilities	1,805,015	3,173,218
Other liabilities	123,985	847,215
Lease liabilities	248,885	339,846
Warrant derivative	531,228	8,508,764
Total current liabilities	2,709,113	12,869,043
Non-current liabilities
Contract liability	6,730,287	6,730,287
Lease liabilities	153,174	166,429
Total non-current liabilities	6,883,461	6,896,716
Total liabilities	9,592,574	19,765,759
Commitments and contingencies
Shareholders’ equity (deficit)
Share capital   Authorized: unlimited   Issued: December 31, 2020 – 46,166,980 December 31, 2019 – 32,198,453	356,824,172	311,077,859
Warrants	3,617,570	3,617,570
Contributed surplus	31,022,356	29,338,849
Accumulated other comprehensive income	400,225	464,101
Accumulated deficit	(367,111,330)	(344,606,273)
Total shareholders’ equity (deficit)	24,752,993	(107,894)
Total liabilities and shareholders' equity (deficit)	$ 34,345,567	$ 19,657,865

CONSOLIDATED STATEMENTS OF FI_2

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)	Dec. 31, 2019shares
Shareholders’ equity (deficit)
Share capital issued (shares)	32,198,453

CONSOLIDATED STATEMENTS OF LOSS

CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Expenses
Research and development	$ 12,944,510	$ 10,817,997	$ 10,027,994
Operating	12,514,496	9,558,641	7,244,791
Loss before the following	(25,459,006)	(20,376,638)	(17,272,785)
Change in fair value of warrant derivative	3,491,928	(12,608,808)	0
Foreign exchange (loss) gain	(659,173)	(316,719)	610,106
Interest income, net	121,194	179,277	173,496
Loss before income taxes	(22,505,057)	(33,122,888)	(16,489,183)
Income tax expense	0	0	(548,042)
Net loss	(22,505,057)	(33,122,888)	(17,037,225)
Other comprehensive (loss) income items that may be reclassified to net loss
Translation adjustment	(63,876)	(143,403)	233,774
Net comprehensive loss	$ (22,568,933)	$ (33,266,291)	$ (16,803,451)
Basic and diluted loss per common share (cad per share)	$ (0.56)	$ (1.50)	$ (1.06)
Weighted average number of shares (basic) (shares)	40,338,789	22,137,990	16,016,366
Weighted average number of shares (diluted) (shares)	40,338,789	22,137,990	16,016,366

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)	CAD ($)	USD ($)	At-the-market agreementCAD ($)	Public OfferingCAD ($)	Share Purchase AgreementCAD ($)	Share Capital $CAD ($)	Share Capital $At-the-market agreementCAD ($)	Share Capital $Public OfferingCAD ($)	Share Capital $Share Purchase AgreementCAD ($)	Warrants $CAD ($)	Contributed Surplus $CAD ($)	Accumulated Other Comprehensive Income $CAD ($)	Accumulated Deficit $CAD ($)
Equity at Dec. 31, 2017	$ 8,283,846					$ 271,710,138				$ 3,617,900	$ 27,028,238	$ 373,730	$ (294,446,160)
Equity at Dec. 31, 2017	8,283,846					271,710,138				3,617,900	27,028,238	373,730	(294,446,160)
Net loss and other comprehensive income	(16,803,451)											233,774	(17,037,225)
Issued pursuant to incentive share award plan	0					109,751					(109,751)
Issued pursuant to stock option plan	123,538					197,245					(73,707)
Issued			$ 620,010	$ 11,606,882	$ 3,314,097		$ 620,010	$ 11,606,882	$ 3,314,097
Issued pursuant to warrant agreement	1,417	$ (330)				1,747				(330)
Share-based compensation	1,415,833										1,415,833
Share issue costs	(2,366,809)					(2,366,809)
Equity at Dec. 31, 2018	6,195,363					285,193,061				3,617,570	28,260,613	607,504	(311,483,385)
Equity at Dec. 31, 2018	6,195,363					285,193,061				3,617,570	28,260,613	607,504	(311,483,385)
Net loss and other comprehensive income	(33,266,291)											(143,403)	(33,122,888)
Issued pursuant to incentive share award plan	0					391,917					(391,917)
Issued			8,476,454	$ 3,314,429	$ 5,403,385		8,476,454	$ 3,314,429	$ 5,403,385
Issued pursuant to warrant agreement	9,152,869					9,152,869
Share-based compensation	1,470,153										1,470,153
Share issue costs	(854,256)					(854,256)
Equity at Dec. 31, 2019	(107,894)					311,077,859				3,617,570	29,338,849	464,101	(344,606,273)
Net loss and other comprehensive income	(22,568,933)											(63,876)	(22,505,057)
Issued pursuant to incentive share award plan	0					732,367					(732,367)
Issued pursuant to stock option plan	241,922					385,022					(143,100)
Issued			$ 40,037,786				$ 40,037,786
Issued pursuant to warrant agreement	6,332,778					6,332,778
Share-based compensation	2,558,974										2,558,974
Share issue costs	(1,741,640)					(1,741,640)
Equity at Dec. 31, 2020	$ 24,752,993					$ 356,824,172				$ 3,617,570	$ 31,022,356	$ 400,225	$ (367,111,330)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Activities
Net loss for the year	$ (22,505,057)	$ (33,122,888)	$ (17,037,225)
Depreciation - property and equipment	88,957	122,982	95,375
Depreciation - right-of-use assets	357,230	362,592	0
Share-based compensation	2,558,974	1,470,153	1,415,833
Interest expense on lease liabilities	68,526	94,817	0
Unrealized foreign exchange loss (gain)	645,078	353,189	(374,337)
Onerous lease contract	0	0	67,588
Amortization - lease incentive liability	0	0	8,189
Change in fair value of warrant derivative	(3,491,928)	12,608,808	0
Net change in non-cash working capital	209,779	(1,795,777)	3,904,339
Cash used in operating activities	(22,068,441)	(19,906,124)	(11,920,238)
Investing Activities
Acquisition of property and equipment	(29,305)	(10,905)	(107,466)
Cash used in investing activities	(29,305)	(10,905)	(107,466)
Financing Activities
Proceeds from exercise of stock options	241,922	0	123,538
Payment of lease liabilities	(460,724)	(447,497)	0
Cash provided by financing activities	39,773,804	21,015,596	13,299,136
Increase in cash	17,676,058	1,098,567	1,271,432
Cash and cash equivalents, beginning of year	14,148,021	13,699,881	11,836,119
Impact of foreign exchange on cash and cash equivalents	(604,505)	(650,427)	592,330
Cash and cash equivalents, end of year	31,219,574	14,148,021	13,699,881
Warrant Derivative And Shares Under Warrant Agreement
Financing Activities
Proceeds from share issuance	1,696,460	3,465,867	1,417
Common Stock Purchase Agreement
Financing Activities
Proceeds from share issuance	0	5,360,247	2,533,980
At-the-market agreement
Financing Activities
Proceeds from share issuance	38,296,146	8,131,620	451,675
Public offering
Financing Activities
Proceeds from share issuance	$ 0	$ 4,505,359	$ 10,188,526

Incorporation and Nature of Ope

Incorporation and Nature of Operations	12 Months Ended
	Dec. 31, 2020
Disclosure Of Notes And Other Explanatory Information [Abstract]
Incorporation and Nature of Operations	Incorporation and Nature of Operations Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. Our consolidated financial statements for the year ended December 31, 2020, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March 4, 2021. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our principal place of business is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada. We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies.

Basis of Financial Statement Pr

Basis of Financial Statement Presentation	12 Months Ended
	Dec. 31, 2020
Corporate Information And Statement Of IFRS Compliance [Abstract]
Basis of Financial Statement Presentation	Basis of Financial Statement Presentation Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (U.S.) Inc., and Oncolytics Biotech (U.K.) Ltd. and are presented in Canadian dollars, our functional currency. The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements. These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). Basis of consolidation Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation. A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Summary Of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below. Deferred income taxes We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity. Financial instruments Classification and measurement Financial assets Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. Under IFRS 9 Financial Instruments ("IFRS 9") , financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company’s business model for managing the assets; and whether the financial asset’s contractual cash flows represent ‘solely payments of principal and interest’ on the principal amount outstanding (the ‘SPPI criterion’). Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. Financial liabilities Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL. Impairment Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset’s original effective interest rate. Derecognition A financial asset is derecognized when: • the contractual rights to the cash flows from the financial asset expire, or • we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired. Fair Value Measurement Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. Foreign currency translation The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss. Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss. Loss per common share Basic loss per common share is determined using the weighted average number of common shares outstanding during the period. We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding “in the money” options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period. Property and equipment Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates: Office equipment and furniture 20% Medical equipment 20% Computer equipment 30% Leasehold improvements Straight-line over the term of the lease Leases At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether: • the contract involves the use of an identified asset; • we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and • we have the right to direct the use of the identified asset. A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended. We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component. We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. Research and development costs Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods. Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed. Revenue recognition Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables. The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known. The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured. Contract receivable - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer’s credit risk and payment histories, including payments made subsequent to year-end. Contract liability - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue. Share-based payments Stock option plan We have one stock option plan (the “Option Plan”) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the “Board”). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management’s estimate of the number of options that are expected to vest. Incentive share award plan Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.

Significant Judgments, Estimate

Significant Judgments, Estimates and Assumptions	12 Months Ended
	Dec. 31, 2020
Significant Judgments, Estimates And Assumptions [Abstract]
Significant Judgments, Estimates and Assumptions	Significant Judgments, Estimates and Assumptions During 2020, the global outbreak of a novel coronavirus identified as the SARS-coronavirus-2 (SARS-CoV-2) led to the associated coronavirus infectious disease 2019 (COVID-19). The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. We considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December 31, 2020, our future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods. Judgments The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods. Estimates and assumptions Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include: Revenue recognition We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables. Clinical trial expenses Clinical trial expenses represent a significant component of our research and development expenses and we outsource a significant portion of these activities to third-party contract research organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that have been performed by the contract research organizations. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified. Valuation of share-based payments Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and forfeiture rate and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. Valuation of warrant derivative Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of the warrant derivative are disclosed in Note 8. Income taxes Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets. Leases We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset. We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used. We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.

Cash Equivalents

Cash Equivalents	12 Months Ended
	Dec. 31, 2020
Cash Equivalents And Short Term Investments [Abstract]
Cash Equivalents	Cash Equivalents Cash Equivalents Cash equivalents consist of interest bearing deposits with our bank totaling $30,361,591 (December 31, 2019 – $13,058,092). The current annual interest rate earned on these deposits is 0.36% (December 31, 2019 – 1.17%).

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [abstract]
Property and Equipment	Property and Equipment Medical Equipment Computer Equipment Office Furniture Office Equipment Leasehold Improvements Total Cost As at December 31, 2018 60,378 345,941 247,438 105,229 498,367 1,257,353 Additions, net of foreign exchange impact — 7,014 — — — 7,014 Disposals — — — — — — As at December 31, 2019 60,378 352,955 247,438 105,229 498,367 1,264,367 Additions, net of foreign exchange impact 1,134 27,719 — — — 28,853 Disposals — (15,137) — — — (15,137) As at December 31, 2020 61,512 365,537 247,438 105,229 498,367 1,278,083 Amortization As at December 31, 2018 24,464 174,953 157,749 72,828 414,623 844,617 Depreciation expense 20,244 49,093 14,668 5,342 33,635 122,982 Disposals — — — — — — As at December 31, 2019 44,708 224,046 172,417 78,170 448,258 967,599 Depreciation expense 2,942 40,024 7,988 4,320 33,683 88,957 Disposals — (15,137) — — — (15,137) As at December 31, 2020 47,650 248,933 180,405 82,490 481,941 1,041,419 Net book value As at December 31, 2020 13,862 116,604 67,033 22,739 16,426 236,664 As at December 31, 2019 15,670 128,909 75,021 27,059 50,109 296,768

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Presentation of leases for lessee [abstract]
Leases	Leases Our portfolio of leases consists of office spaces with lease terms generally between 3 to 5 years. We currently do not have leases with variable lease payments, residual value guarantees, or leases not yet commenced to which we are committed. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was 15%. During 2020, we entered into an office space lease for one of our subsidiaries. We recognized a $297,373 right-of-use asset and a lease liability of the same amount. The lease provided for one extension option that we were not reasonably certain to exercise at lease commencement date. Right-of-use assets Office Spaces As at January 1, 2019 808,025 Depreciation expense (362,592) Foreign exchange impact (14,720) As at December 31, 2019 430,713 Additions 297,373 Depreciation expense (357,230) Foreign exchange impact 1,612 As at December 31, 2020 372,468 Lease liabilities Office Spaces As at January 1, 2019 882,437 Payment of lease liabilities (447,497) Interest expense on lease liabilities 94,817 Foreign exchange impact (23,482) As at December 31, 2019 506,275 Additions 297,373 Payment of lease liabilities (460,724) Interest expense on lease liabilities 68,526 Foreign exchange impact (9,391) As at December 31, 2020 402,059 Our total undiscounted lease liability as at December 31, 2020 is as follows: Maturity analysis - contractual undiscounted cash flows December 31, 2020 Less than one year 286,509 One to five years 172,003 More than five years — Total undiscounted lease liability 458,512

Warrant Derivative

Warrant Derivative	12 Months Ended
	Dec. 31, 2020
Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]
Warrant Derivative	Warrant Derivative On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share and one common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. Under IFRS 9 Financial Instruments and IAS 32 Financial Instruments: Presentation , warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of US$0.90 meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. A reconciliation of the change in fair value of the warrant derivative is as follows: Number of Warrants Outstanding Fair Value of Warrant Derivative Issued, August 16, 2019 4,619,773 1,657,214 Exercised (2,935,647) (5,687,003) Change in fair value — 12,608,808 Foreign exchange impact — (70,255) As at December 31, 2019 1,684,126 8,508,764 Exercised (1,418,369) (4,636,317) Change in fair value — (3,491,928) Foreign exchange impact — 150,709 As at December 31, 2020 265,757 531,228 In 2020, we received cash proceeds of US$1,276,532 (2019 - US$2,642,082) with respect to the warrants exercised. We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. The estimated fair value of the warrant derivative was determined using the following assumptions: December 31, 2020 December 31, 2019 Fair value per warrant US$1.57 US$3.89 Underlying share price US$2.38 US$4.76 Risk-free interest rate 0.10% 1.59% Expected hold period to exercise 1.0 year 1.0 year Expected share price volatility 90.00% 90.00% Expected dividend yield Nil Nil

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2020
Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]
Share Capital	Share Capital Authorized: Unlimited number of no par value common shares Share Consolidation: On May 22, 2018, we completed the consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Shares Number Amount Balance, December 31, 2017 141,805,722 271,710,138 Issued pursuant to "At the Market" (ATM) equity distribution agreement (a) 519,500 553,650 Share issue costs — (33,335) Issued pursuant to stock option plan 71,000 38,269 Balance, May 22, 2018 - pre-consolidation 142,396,222 272,268,722 Balance, May 22, 2018 - post-consolidation 14,988,995 272,268,722 Issued pursuant to public offering (b) 1,532,278 11,606,882 Issued pursuant to equity warrants exercised (see "— Equity Warrants " ) 157 1,747 Issued pursuant to stock option plan 34,329 158,976 Issued pursuant to incentive share award plan 28,297 109,751 Issued pursuant to Common Stock Purchase Agreement (c) 797,691 3,314,097 Issued pursuant to "At the Market" (ATM) equity distribution agreement (d) 18,002 66,360 Share issue costs — (2,333,474) Balance, December 31, 2018 17,399,749 285,193,061 Issued pursuant to incentive share award plan 323,301 391,917 Issued pursuant to Common Stock Purchase Agreement (c) 2,494,943 5,403,385 Issued pursuant to "At the Market" (ATM) equity distribution agreement (d) 4,425,040 8,476,454 Issued pursuant to public offering (e) 4,619,773 3,314,429 Issued pursuant to warrant derivative exercised (e) 2,935,647 9,152,869 Share issue costs — (854,256) Balance, December 31, 2019 32,198,453 311,077,859 Issued pursuant to stock option plan 133,454 385,022 Issued pursuant to incentive share award plan 234,172 732,367 Issued pursuant to "At the Market" (ATM) equity distribution agreement (d)(f) 12,182,532 40,037,786 Issued pursuant to warrant derivative exercised (e) 1,418,369 6,332,778 Share issue costs — (1,741,640) Balance, December 31, 2020 46,166,980 356,824,172 (a) On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allowed us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace” (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Our Canadian ATM allowed us, at our sole discretion, to determine the timing and number of shares to be sold under this ATM facility. During 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for gross proceeds of $553,650. We incurred share issue costs of $33,335. This sales agreement expired on March 16, 2018. (b) On June 5, 2018, pursuant to an underwritten public offering, 1,532,278 common shares were sold at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356. (c) On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US$1.00 per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the five In 2020, we sold nil (2019 - 2,477,665; 2018 - 678,182) common shares for gross proceeds of nil (2019 - US$4,055,725; 2018 - US$2,055,207) and issued nil (2019 - 17,278; 2018 - 119,509) commitment shares. The commitment shares were fair valued at nil (2019 - US$29,758; 2018 - US$483,690) and were recorded as share issue costs in addition to cash share issue costs of nil (2019 - $3,757; 2018 - $208,726). (d) On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 6,741,518 (2019 - 4,425,040; 2018 - 18,002) common shares for gross proceeds of US$17,538,342 (2019 - US$6,390,691; 2018 - US$50,046) at an average price of US$2.42 (2019 - US$1.70; 2018 - US$2.85). We received, net of commissions of US$526,150 (2019 - US$191,721; 2018 - US$1,501), proceeds of US$17,012,192 (2019 - US$6,198,970; 2018 - US$48,545). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834; 2018 - $135,000). This sales agreement expired on June 4, 2020. (e) On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2020, our share capital included fair value of $4,636,317 (2019 - 5,687,003) in addition to gross proceeds of US$1,276,532 (2019 - US$2,642,082) for the 1,418,369 (2019 - 2,935,647) warrants that were exercised (see Note 8). (f) On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 5,441,014 common shares for gross proceeds of US$12,628,775 at an average price of US$2.11. We received, net of commissions of US$378,863, proceeds of US$12,249,911. In total, we incurred share issue costs (including commissions) of $884,886. Equity Warrants On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Following the Share Consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity. The following table summarizes our outstanding equity warrants: Number of Warrants Outstanding (1) Warrant Balance, December 31, 2017 16,445,000 3,617,900 Issued pursuant to equity warrant exercised (1,500) (330) Balance, December 31, 2018 16,443,500 3,617,570 Balance, December 31, 2019 16,443,500 3,617,570 Balance, December 31, 2020 16,443,500 3,617,570

Share Based Payments

Share Based Payments	12 Months Ended
	Dec. 31, 2020
Disclosure Of Share-based Payment Arrangements [Abstract]
Share Based Payments	Share-Based Payments Stock Option Plan We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at December 31: 2020 2019 2018 Stock Options Weighted Average Exercise Price Stock Options Weighted Average Exercise Price Stock Options Weighted Average Exercise Price Outstanding, beginning of the year 2,246,947 5.31 1,249,361 8.73 647,156 13.20 Granted during the year 1,817,500 3.19 1,020,000 1.42 750,467 4.97 Forfeited during the year (141,418) 3.84 (12,839) 11.35 (105,338) 11.67 Expired during the year (25,520) 62.49 (9,575) 29.07 (1,122) 13.78 Exercised during the year (133,454) 1.81 — — (41,802) 2.96 Outstanding, end of the 3,764,055 4.08 2,246,947 5.31 1,249,361 8.73 Options exercisable, end of the year 2,164,551 4.84 1,327,845 7.22 777,245 11.04 The following table summarizes information about the stock options outstanding and exercisable at December 31, 2020: Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.54 - $1.79 808,333 3.03 1.39 545,009 1.37 $1.80 - $3.01 459,730 4.49 2.66 289,730 2.68 $3.02 - $3.90 1,834,706 3.86 3.21 769,696 3.26 $3.91 - $7.41 493,252 2.68 6.13 392,082 6.02 $7.42 - $52.63 168,034 2.32 24.32 168,034 24.32 3,764,055 3.53 4.08 2,164,551 4.84 Non-exercisable options vest annually over periods ranging from one We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: 2020 2019 2018 Risk-free interest rate 0.34% 1.62% 2.02% Expected hold period to exercise 3.0 years 3.0 years 3.0 years Expected share price volatility 110.82% 97.9% 81.15% Expected forfeiture rate 3.67% 3.67% 3.67% Expected dividend yield Nil Nil Nil Weighted average fair value of options $2.12 $0.87 $2.67 Incentive Share Award Plan Restricted Share Units We have issued RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three 2020 2019 2018 Outstanding, beginning of the year 209,657 260,755 190,407 Granted during the year 154,923 270,098 102,855 Forfeited during the year — — (4,210) Released during the year (229,962) (321,196) (28,297) Outstanding, end of the year 134,618 209,657 260,755 (1) The weighted average fair value of the RSUs granted was $2.41 in 2020 (2019 - $0.80 ; 2018 - $3.35). Performance Share Units We have also issued PSUs to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after 3 years or vest over a three 2020 2019 2018 Outstanding, beginning of the year 61,051 63,156 94,734 Forfeited during the year — — (31,578) Released during the year (4,210) (2,105) — Outstanding, end of the year 56,841 61,051 63,156

Loss Per Common Share

Loss Per Common Share	12 Months Ended
	Dec. 31, 2020
Earnings per share [abstract]
Loss Per Common Share	Loss Per Common Share Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended December 31, 2020 of 40,338,789 (2019 - 22,137,990; 2018 - 16,016,366). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.

Contract Liability and Receivab

Contract Liability and Receivable	12 Months Ended
	Dec. 31, 2020
Disclosure of revenue from contracts with customers [Abstract]
Contract Liability and Receivable	Contract Liability and Receivable Regional licensing agreement We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. Contract liability Our contract liability balance at December 31, which w e expect to record in revenue over the next five years, is as follows: 2020 2019 Balance, beginning of the year 6,730,287 6,730,287 Regional licensing agreement — — Revenue recognized in the year — — Balance, end of the year 6,730,287 6,730,287 Contract liability - current — — Contract liability - non-current 6,730,287 6,730,287 6,730,287 6,730,287

Commitments

Commitments	12 Months Ended
	Dec. 31, 2020
Commitments [Abstract]
Commitments	Commitments We are committed to payments totaling $9,360,653 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. Our commitments include the committed payments related to our collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1, as this phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December 31, 2020, we recorded nil (December 31, 2019 - US$1,500,000) in other receivables related to an upfront payment of BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and US$97,381 (December 31, 2019 - US$652,306) in other liabilities representing future trial costs to be incurred. Under a clinical trial agreement entered into with the Alberta Cancer Board (“ACB”), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product. We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2020
Contingencies [Abstract]
Contingencies	Contingencies Assumption Agreement In 1999, we entered into an agreement that assumed certain obligations (the “Assumption Agreement”) in connection with a Share Purchase Agreement (the “Share Purchase Agreement”) between SYNSORB and our former shareholders to make milestone payments and royalty payments. As of December 31, 2020, a milestone payment was still outstanding for $1.0 million, due within 90 days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep. This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes. In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep. If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders 10.75% (2019 - 10.75%) of the royalty payments and other payments received. Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of 2.15% (2019 - 2.15%) of Net Sales received for such products. BRI “Work in Kind” Contribution

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Disclosure of income tax [Abstract]
Income Taxes	Income Taxes The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows: 2020 2019 2018 Loss before income taxes (22,505,057) (33,122,888) (16,489,183) Statutory Canadian corporate tax rate 24.00 % 26.50 % 27.00 % Anticipated tax recovery (5,401,214) (8,777,565) (4,452,079) Foreign jurisdiction tax rate difference 3,237,898 3,088,811 3,312,963 Employee share-based compensation 614,154 389,591 382,275 Change in fair value of warrant derivative (838,063) 3,341,334 — Impact of Alberta rate change 96,028 3,758,175 — Adjustment to opening tax pools 20,711 11,973 (238,222) Other permanent differences 108,945 149,294 (35,912) Change in deferred tax benefits deemed not probable to 2,161,541 (1,961,613) 1,579,017 Current income taxes — — 548,042 Adjustment in respect to prior periods — — — Net current tax expense — — 548,042 As at December 31, 2020, we have the following non-capital losses for income tax purposes in Canada: Expiry $ 2026 9,809,000 2027 12,170,000 2029 4,009,000 2030 4,774,000 2031 4,343,000 2032 2,873,000 2033 2,457,000 2034 2,472,000 2035 3,125,000 2036 6,430,000 2037 4,812,000 2038 5,056,000 2039 6,864,000 2040 9,800,000 78,994,000 As at December 31, 2020, we have the following non-refundable federal investment tax credits for income tax purposes in Canada: Expiry $ 2021 471,000 2022 465,000 2023 361,000 2024 228,000 2025 271,000 2026 520,000 2027 596,000 2028 622,000 2029 173,000 2030 91,000 2031 114,000 2032 381,000 2033 487,000 2034 270,000 2035 183,000 2036 41,000 2037 980 2038 22,000 2039 8,000 5,304,980 As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years’ taxable income of approximately $27,660,000. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows: 2020 2019 2018 Net operating losses carried forward 21,487,804 19,625,642 20,664,345 Scientific research and experimental development 6,362,152 6,338,542 7,406,169 Investment tax credits 4,068,105 4,222,016 3,988,606 Undepreciated capital costs in excess of book value of property and equipment and intellectual property 1,927,709 1,908,320 1,949,611 Share issue costs 689,193 611,072 696,346 Net capital losses carried forward 6,472 6,474 7,598 Unrecognized deferred tax asset 34,541,435 32,712,066 34,712,675

Capital Disclosures

Capital Disclosures	12 Months Ended
	Dec. 31, 2020
Statement of changes in equity [abstract]
Capital Disclosures	Capital Disclosures Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection. We include shareholders’ equity and cash and cash equivalents in the definition of capital. 2020 2019 Cash and cash equivalents 31,219,574 14,148,021 Shareholders’ equity (deficit) 24,752,993 (107,894) We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of pelareorep. In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year’s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board. Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital. There are no assurances that funds will be made available to us when required. On June 12, 2020, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement. Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022. Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 (see Note 9). We will use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2020.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2020
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	Financial Instruments Our financial instruments consist of cash and cash equivalents, other receivables, other liabilities, accounts payable and warrant derivative. As at December 31, 2020, the carrying amount of our cash and cash equivalents, other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2020, the fair value of our warrant derivative was $531,228 (December 31, 2019 - $8,508,764). Credit risk Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations. We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll. Interest rate risk Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates. We are exposed to interest rate risk through our cash and cash equivalents. We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements. Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held. Foreign exchange risk Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2020 by approximately $172,000. The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $20,000. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $3,000. We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable. Balances in foreign currencies at December 31, 2020 are as follows: U.S. dollars $ British pounds £ Euro Cash and cash equivalents 23,134,113 26,768 37,347 Accounts payable and other liabilities (455,588) (2,244) (930) Warrant derivative (417,238) — — 22,261,287 24,524 36,417 Liquidity risk Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable are all due within the current operating period.

Additional Cash Flow Disclosure

Additional Cash Flow Disclosures	12 Months Ended
	Dec. 31, 2020
Statement of cash flows [abstract]
Additional Cash Flow Disclosures	Additional Cash Flow Disclosures Net Change In Non-Cash Working Capital 2020 2019 2018 Change in: Contract receivable — — 4,767,100 Other receivables 1,979,111 (2,017,122) (13,924) Prepaid expenses 286,391 (2,012,605) 475,077 Accounts payable and accrued liabilities (1,368,203) 1,347,365 (1,858,170) Contract liability — — 547,707 Other liabilities (723,230) 807,877 (27,982) Non-cash impact of foreign exchange 35,710 78,708 14,531 Change in non-cash working capital related to operating activities 209,779 (1,795,777) 3,904,339 Other Cash Flow Disclosures 2020 2019 2018 Cash interest received 189,720 274,094 173,496 Cash taxes paid 12,080 5,448 15,728

Indemnification of Officers and

Indemnification of Officers and Directors	12 Months Ended
	Dec. 31, 2020
Disclosure Of Indemnification Of Officers and Directors [Abstract]
Indemnification of Officers and Directors	Indemnification of Officers and Directors Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company. The by-laws provide no limit to the amount of the indemnification. We have purchased directors’ and officers’ insurance coverage to cover claims made against the directors and officers during the applicable policy periods. The amounts and types of coverage have varied from period to period as dictated by market conditions. We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies. There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.

Economic Dependence

Economic Dependence	12 Months Ended
	Dec. 31, 2020
Disclosure Of Economic Dependence [Abstract]
Economic Dependence	Economic Dependence We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade pelareorep required for our clinical trial program. Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program. We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale. We have attempted to mitigate this risk by producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.

Other Expenses and Adjustments

Other Expenses and Adjustments	12 Months Ended
	Dec. 31, 2020
Analysis of income and expense [abstract]
Other Expenses and Adjustments	Other Expenses and AdjustmentsThe following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange (loss) gain as presented separately on the face of the consolidated statement of loss and comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include personnel costs and expenses paid to third parties. 2020 2019 2018 Included in research and development expenses: Non-cash share-based compensation 1,043,373 561,420 680,541 Included in operating expenses Depreciation - property and equipment 88,957 122,982 95,375 Depreciation - right-of-use assets 357,230 362,592 — Non-cash share-based compensation 1,515,601 908,733 735,292 Transaction cost, warrant derivative — 233,143 — Onerous lease contract — — 67,588 Amortization - lease incentive liability — — 8,189

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Disclosure of related party [Abstract]
Related Party Transactions	Related Party Transactions Compensation of Key Management Personnel Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company. 2020 2019 2018 Short-term employee compensation and benefits 3,514,527 3,786,667 2,680,621 Termination benefits 495,175 — — Share-based payments 1,757,723 1,123,408 1,067,195 5,767,425 4,910,075 3,747,816

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Disclosure of events after reporting period [Abstract]
Subsequent Events	Subsequent EventsBetween January 1, 2021 and March 4, 2021, through our June 2020 ATM equity distribution agreement, we issued 5,685,097 common shares for gross proceeds of US$18,503,188 at an average price of US$2.85. We received, net of commissions of US$555,096, proceeds of US$17,948,092.

Comparative Figures

Comparative Figures	12 Months Ended
	Dec. 31, 2020
Comparative figures [Abstract]
Comparative Figures	Comparative FiguresReclassification was made to prior period's figure to conform to the current period's presentation.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Summary Of Significant Accounting Policies [Abstract]
Deferred income taxes	We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.
Financial assets	Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. Under IFRS 9 Financial Instruments ("IFRS 9") , financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company’s business model for managing the assets; and whether the financial asset’s contractual cash flows represent ‘solely payments of principal and interest’ on the principal amount outstanding (the ‘SPPI criterion’).
Financial liabilities	Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.
Impairment	Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset’s original effective interest rate.
Derecognition	A financial asset is derecognized when: • the contractual rights to the cash flows from the financial asset expire, or • we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity.
Fair value measurement	Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.
Foreign currency translation	The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss. Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.
Loss per common share	Basic loss per common share is determined using the weighted average number of common shares outstanding during the period. We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding “in the money” options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.
Property and equipment	Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates: Office equipment and furniture 20% Medical equipment 20% Computer equipment 30% Leasehold improvements Straight-line over the term of the lease
Leases	At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether: • the contract involves the use of an identified asset; • we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and • we have the right to direct the use of the identified asset. A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended. We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.
Research and development costs	Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed.
Revenue recognition	Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables. The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known. The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured. Contract receivable - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer’s credit risk and payment histories, including payments made subsequent to year-end. Contract liability - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.
Share based payments	Stock option plan We have one stock option plan (the “Option Plan”) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the “Board”). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management’s estimate of the number of options that are expected to vest. Incentive share award plan Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Summary Of Significant Accounting Policies [Abstract]
Schedule of depreciation rates	Depreciation is recorded using the declining balance method at the following annual rates: Office equipment and furniture 20% Medical equipment 20% Computer equipment 30% Leasehold improvements Straight-line over the term of the lease Medical Equipment Computer Equipment Office Furniture Office Equipment Leasehold Improvements Total Cost As at December 31, 2018 60,378 345,941 247,438 105,229 498,367 1,257,353 Additions, net of foreign exchange impact — 7,014 — — — 7,014 Disposals — — — — — — As at December 31, 2019 60,378 352,955 247,438 105,229 498,367 1,264,367 Additions, net of foreign exchange impact 1,134 27,719 — — — 28,853 Disposals — (15,137) — — — (15,137) As at December 31, 2020 61,512 365,537 247,438 105,229 498,367 1,278,083 Amortization As at December 31, 2018 24,464 174,953 157,749 72,828 414,623 844,617 Depreciation expense 20,244 49,093 14,668 5,342 33,635 122,982 Disposals — — — — — — As at December 31, 2019 44,708 224,046 172,417 78,170 448,258 967,599 Depreciation expense 2,942 40,024 7,988 4,320 33,683 88,957 Disposals — (15,137) — — — (15,137) As at December 31, 2020 47,650 248,933 180,405 82,490 481,941 1,041,419 Net book value As at December 31, 2020 13,862 116,604 67,033 22,739 16,426 236,664 As at December 31, 2019 15,670 128,909 75,021 27,059 50,109 296,768

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of property and equipment	Depreciation is recorded using the declining balance method at the following annual rates: Office equipment and furniture 20% Medical equipment 20% Computer equipment 30% Leasehold improvements Straight-line over the term of the lease Medical Equipment Computer Equipment Office Furniture Office Equipment Leasehold Improvements Total Cost As at December 31, 2018 60,378 345,941 247,438 105,229 498,367 1,257,353 Additions, net of foreign exchange impact — 7,014 — — — 7,014 Disposals — — — — — — As at December 31, 2019 60,378 352,955 247,438 105,229 498,367 1,264,367 Additions, net of foreign exchange impact 1,134 27,719 — — — 28,853 Disposals — (15,137) — — — (15,137) As at December 31, 2020 61,512 365,537 247,438 105,229 498,367 1,278,083 Amortization As at December 31, 2018 24,464 174,953 157,749 72,828 414,623 844,617 Depreciation expense 20,244 49,093 14,668 5,342 33,635 122,982 Disposals — — — — — — As at December 31, 2019 44,708 224,046 172,417 78,170 448,258 967,599 Depreciation expense 2,942 40,024 7,988 4,320 33,683 88,957 Disposals — (15,137) — — — (15,137) As at December 31, 2020 47,650 248,933 180,405 82,490 481,941 1,041,419 Net book value As at December 31, 2020 13,862 116,604 67,033 22,739 16,426 236,664 As at December 31, 2019 15,670 128,909 75,021 27,059 50,109 296,768

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Presentation of leases for lessee [abstract]
Right-of-use assets	Right-of-use assets Office Spaces As at January 1, 2019 808,025 Depreciation expense (362,592) Foreign exchange impact (14,720) As at December 31, 2019 430,713 Additions 297,373 Depreciation expense (357,230) Foreign exchange impact 1,612 As at December 31, 2020 372,468
Lease liabilities	Lease liabilities Office Spaces As at January 1, 2019 882,437 Payment of lease liabilities (447,497) Interest expense on lease liabilities 94,817 Foreign exchange impact (23,482) As at December 31, 2019 506,275 Additions 297,373 Payment of lease liabilities (460,724) Interest expense on lease liabilities 68,526 Foreign exchange impact (9,391) As at December 31, 2020 402,059
Total undiscounted lease liability	Our total undiscounted lease liability as at December 31, 2020 is as follows: Maturity analysis - contractual undiscounted cash flows December 31, 2020 Less than one year 286,509 One to five years 172,003 More than five years — Total undiscounted lease liability 458,512

Warrant Derivative (Tables)

Warrant Derivative (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]
Reconciliation of change in fair value of warrant derivative	A reconciliation of the change in fair value of the warrant derivative is as follows: Number of Warrants Outstanding Fair Value of Warrant Derivative Issued, August 16, 2019 4,619,773 1,657,214 Exercised (2,935,647) (5,687,003) Change in fair value — 12,608,808 Foreign exchange impact — (70,255) As at December 31, 2019 1,684,126 8,508,764 Exercised (1,418,369) (4,636,317) Change in fair value — (3,491,928) Foreign exchange impact — 150,709 As at December 31, 2020 265,757 531,228 The estimated fair value of the warrant derivative was determined using the following assumptions: December 31, 2020 December 31, 2019 Fair value per warrant US$1.57 US$3.89 Underlying share price US$2.38 US$4.76 Risk-free interest rate 0.10% 1.59% Expected hold period to exercise 1.0 year 1.0 year Expected share price volatility 90.00% 90.00% Expected dividend yield Nil Nil

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]
Schedule of share capital	Shares Number Amount Balance, December 31, 2017 141,805,722 271,710,138 Issued pursuant to "At the Market" (ATM) equity distribution agreement (a) 519,500 553,650 Share issue costs — (33,335) Issued pursuant to stock option plan 71,000 38,269 Balance, May 22, 2018 - pre-consolidation 142,396,222 272,268,722 Balance, May 22, 2018 - post-consolidation 14,988,995 272,268,722 Issued pursuant to public offering (b) 1,532,278 11,606,882 Issued pursuant to equity warrants exercised (see "— Equity Warrants " ) 157 1,747 Issued pursuant to stock option plan 34,329 158,976 Issued pursuant to incentive share award plan 28,297 109,751 Issued pursuant to Common Stock Purchase Agreement (c) 797,691 3,314,097 Issued pursuant to "At the Market" (ATM) equity distribution agreement (d) 18,002 66,360 Share issue costs — (2,333,474) Balance, December 31, 2018 17,399,749 285,193,061 Issued pursuant to incentive share award plan 323,301 391,917 Issued pursuant to Common Stock Purchase Agreement (c) 2,494,943 5,403,385 Issued pursuant to "At the Market" (ATM) equity distribution agreement (d) 4,425,040 8,476,454 Issued pursuant to public offering (e) 4,619,773 3,314,429 Issued pursuant to warrant derivative exercised (e) 2,935,647 9,152,869 Share issue costs — (854,256) Balance, December 31, 2019 32,198,453 311,077,859 Issued pursuant to stock option plan 133,454 385,022 Issued pursuant to incentive share award plan 234,172 732,367 Issued pursuant to "At the Market" (ATM) equity distribution agreement (d)(f) 12,182,532 40,037,786 Issued pursuant to warrant derivative exercised (e) 1,418,369 6,332,778 Share issue costs — (1,741,640) Balance, December 31, 2020 46,166,980 356,824,172 (a) On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allowed us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace” (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Our Canadian ATM allowed us, at our sole discretion, to determine the timing and number of shares to be sold under this ATM facility. During 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for gross proceeds of $553,650. We incurred share issue costs of $33,335. This sales agreement expired on March 16, 2018. (b) On June 5, 2018, pursuant to an underwritten public offering, 1,532,278 common shares were sold at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356. (c) On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US$1.00 per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the five In 2020, we sold nil (2019 - 2,477,665; 2018 - 678,182) common shares for gross proceeds of nil (2019 - US$4,055,725; 2018 - US$2,055,207) and issued nil (2019 - 17,278; 2018 - 119,509) commitment shares. The commitment shares were fair valued at nil (2019 - US$29,758; 2018 - US$483,690) and were recorded as share issue costs in addition to cash share issue costs of nil (2019 - $3,757; 2018 - $208,726). (d) On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 6,741,518 (2019 - 4,425,040; 2018 - 18,002) common shares for gross proceeds of US$17,538,342 (2019 - US$6,390,691; 2018 - US$50,046) at an average price of US$2.42 (2019 - US$1.70; 2018 - US$2.85). We received, net of commissions of US$526,150 (2019 - US$191,721; 2018 - US$1,501), proceeds of US$17,012,192 (2019 - US$6,198,970; 2018 - US$48,545). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834; 2018 - $135,000). This sales agreement expired on June 4, 2020. (e) On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2020, our share capital included fair value of $4,636,317 (2019 - 5,687,003) in addition to gross proceeds of US$1,276,532 (2019 - US$2,642,082) for the 1,418,369 (2019 - 2,935,647) warrants that were exercised (see Note 8). (f) On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 5,441,014 common shares for gross proceeds of US$12,628,775 at an average price of US$2.11. We received, net of commissions of US$378,863, proceeds of US$12,249,911. In total, we incurred share issue costs (including commissions) of $884,886.
Summary of outstanding warrants	The following table summarizes our outstanding equity warrants: Number of Warrants Outstanding (1) Warrant Balance, December 31, 2017 16,445,000 3,617,900 Issued pursuant to equity warrant exercised (1,500) (330) Balance, December 31, 2018 16,443,500 3,617,570 Balance, December 31, 2019 16,443,500 3,617,570 Balance, December 31, 2020 16,443,500 3,617,570 The following table summarizes information about the stock options outstanding and exercisable at December 31, 2020: Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.54 - $1.79 808,333 3.03 1.39 545,009 1.37 $1.80 - $3.01 459,730 4.49 2.66 289,730 2.68 $3.02 - $3.90 1,834,706 3.86 3.21 769,696 3.26 $3.91 - $7.41 493,252 2.68 6.13 392,082 6.02 $7.42 - $52.63 168,034 2.32 24.32 168,034 24.32 3,764,055 3.53 4.08 2,164,551 4.84

Share Based Payments (Tables)

Share Based Payments (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of share-based payment arrangement [Abstract]
Schedule of stock options and weighted average exercise prices of share options	We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at December 31: 2020 2019 2018 Stock Options Weighted Average Exercise Price Stock Options Weighted Average Exercise Price Stock Options Weighted Average Exercise Price Outstanding, beginning of the year 2,246,947 5.31 1,249,361 8.73 647,156 13.20 Granted during the year 1,817,500 3.19 1,020,000 1.42 750,467 4.97 Forfeited during the year (141,418) 3.84 (12,839) 11.35 (105,338) 11.67 Expired during the year (25,520) 62.49 (9,575) 29.07 (1,122) 13.78 Exercised during the year (133,454) 1.81 — — (41,802) 2.96 Outstanding, end of the 3,764,055 4.08 2,246,947 5.31 1,249,361 8.73 Options exercisable, end of the year 2,164,551 4.84 1,327,845 7.22 777,245 11.04
Schedule of stock options outstanding and exercisable by range of exercise price	The following table summarizes information about the stock options outstanding and exercisable at December 31, 2020: Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.54 - $1.79 808,333 3.03 1.39 545,009 1.37 $1.80 - $3.01 459,730 4.49 2.66 289,730 2.68 $3.02 - $3.90 1,834,706 3.86 3.21 769,696 3.26 $3.91 - $7.41 493,252 2.68 6.13 392,082 6.02 $7.42 - $52.63 168,034 2.32 24.32 168,034 24.32 3,764,055 3.53 4.08 2,164,551 4.84
Schedule of weighted average remaining contractual life and outstanding stock options by exercise price	The following table summarizes our outstanding equity warrants: Number of Warrants Outstanding (1) Warrant Balance, December 31, 2017 16,445,000 3,617,900 Issued pursuant to equity warrant exercised (1,500) (330) Balance, December 31, 2018 16,443,500 3,617,570 Balance, December 31, 2019 16,443,500 3,617,570 Balance, December 31, 2020 16,443,500 3,617,570 The following table summarizes information about the stock options outstanding and exercisable at December 31, 2020: Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.54 - $1.79 808,333 3.03 1.39 545,009 1.37 $1.80 - $3.01 459,730 4.49 2.66 289,730 2.68 $3.02 - $3.90 1,834,706 3.86 3.21 769,696 3.26 $3.91 - $7.41 493,252 2.68 6.13 392,082 6.02 $7.42 - $52.63 168,034 2.32 24.32 168,034 24.32 3,764,055 3.53 4.08 2,164,551 4.84
Disclosure weighted average assumptions and fair value of options	The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: 2020 2019 2018 Risk-free interest rate 0.34% 1.62% 2.02% Expected hold period to exercise 3.0 years 3.0 years 3.0 years Expected share price volatility 110.82% 97.9% 81.15% Expected forfeiture rate 3.67% 3.67% 3.67% Expected dividend yield Nil Nil Nil Weighted average fair value of options $2.12 $0.87 $2.67
Schedule of number of other equity instruments	The following RSUs are outstanding at December 31: 2020 2019 2018 Outstanding, beginning of the year 209,657 260,755 190,407 Granted during the year 154,923 270,098 102,855 Forfeited during the year — — (4,210) Released during the year (229,962) (321,196) (28,297) Outstanding, end of the year 134,618 209,657 260,755 (1) The weighted average fair value of the RSUs granted was $2.41 in 2020 (2019 - $0.80 ; 2018 - $3.35). 2020 2019 2018 Outstanding, beginning of the year 61,051 63,156 94,734 Forfeited during the year — — (31,578) Released during the year (4,210) (2,105) — Outstanding, end of the year 56,841 61,051 63,156

Contract Liability and Receiv_2

Contract Liability and Receivable (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of revenue from contracts with customers [Abstract]
Contract liability balances	Our contract liability balance at December 31, which w e expect to record in revenue over the next five years, is as follows: 2020 2019 Balance, beginning of the year 6,730,287 6,730,287 Regional licensing agreement — — Revenue recognized in the year — — Balance, end of the year 6,730,287 6,730,287 Contract liability - current — — Contract liability - non-current 6,730,287 6,730,287 6,730,287 6,730,287

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of income tax [Abstract]
Provision for income taxes	The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows: 2020 2019 2018 Loss before income taxes (22,505,057) (33,122,888) (16,489,183) Statutory Canadian corporate tax rate 24.00 % 26.50 % 27.00 % Anticipated tax recovery (5,401,214) (8,777,565) (4,452,079) Foreign jurisdiction tax rate difference 3,237,898 3,088,811 3,312,963 Employee share-based compensation 614,154 389,591 382,275 Change in fair value of warrant derivative (838,063) 3,341,334 — Impact of Alberta rate change 96,028 3,758,175 — Adjustment to opening tax pools 20,711 11,973 (238,222) Other permanent differences 108,945 149,294 (35,912) Change in deferred tax benefits deemed not probable to 2,161,541 (1,961,613) 1,579,017 Current income taxes — — 548,042 Adjustment in respect to prior periods — — — Net current tax expense — — 548,042
Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets	As at December 31, 2020, we have the following non-capital losses for income tax purposes in Canada: Expiry $ 2026 9,809,000 2027 12,170,000 2029 4,009,000 2030 4,774,000 2031 4,343,000 2032 2,873,000 2033 2,457,000 2034 2,472,000 2035 3,125,000 2036 6,430,000 2037 4,812,000 2038 5,056,000 2039 6,864,000 2040 9,800,000 78,994,000 As at December 31, 2020, we have the following non-refundable federal investment tax credits for income tax purposes in Canada: Expiry $ 2021 471,000 2022 465,000 2023 361,000 2024 228,000 2025 271,000 2026 520,000 2027 596,000 2028 622,000 2029 173,000 2030 91,000 2031 114,000 2032 381,000 2033 487,000 2034 270,000 2035 183,000 2036 41,000 2037 980 2038 22,000 2039 8,000 5,304,980 Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows: 2020 2019 2018 Net operating losses carried forward 21,487,804 19,625,642 20,664,345 Scientific research and experimental development 6,362,152 6,338,542 7,406,169 Investment tax credits 4,068,105 4,222,016 3,988,606 Undepreciated capital costs in excess of book value of property and equipment and intellectual property 1,927,709 1,908,320 1,949,611 Share issue costs 689,193 611,072 696,346 Net capital losses carried forward 6,472 6,474 7,598 Unrecognized deferred tax asset 34,541,435 32,712,066 34,712,675

Capital Disclosures (Tables)

Capital Disclosures (Tables)	12 Months Ended
	Dec. 31, 2020
Statement of changes in equity [abstract]
Schedule of capital components	2020 2019 Cash and cash equivalents 31,219,574 14,148,021 Shareholders’ equity (deficit) 24,752,993 (107,894)

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of detailed information about financial instruments [abstract]
Schedule of balances in foreign currencies	Balances in foreign currencies at December 31, 2020 are as follows: U.S. dollars $ British pounds £ Euro Cash and cash equivalents 23,134,113 26,768 37,347 Accounts payable and other liabilities (455,588) (2,244) (930) Warrant derivative (417,238) — — 22,261,287 24,524 36,417

Additional Cash Flow Disclosu_2

Additional Cash Flow Disclosures (Tables)	12 Months Ended
	Dec. 31, 2020
Statement of cash flows [abstract]
Net change in non-cash working capital	Net Change In Non-Cash Working Capital 2020 2019 2018 Change in: Contract receivable — — 4,767,100 Other receivables 1,979,111 (2,017,122) (13,924) Prepaid expenses 286,391 (2,012,605) 475,077 Accounts payable and accrued liabilities (1,368,203) 1,347,365 (1,858,170) Contract liability — — 547,707 Other liabilities (723,230) 807,877 (27,982) Non-cash impact of foreign exchange 35,710 78,708 14,531 Change in non-cash working capital related to operating activities 209,779 (1,795,777) 3,904,339
Other cash flow disclosures	Other Cash Flow Disclosures 2020 2019 2018 Cash interest received 189,720 274,094 173,496 Cash taxes paid 12,080 5,448 15,728

Other Expenses and Adjustments

Other Expenses and Adjustments (Tables)	12 Months Ended
	Dec. 31, 2020
Analysis of income and expense [abstract]
Other expenses and adjustments	2020 2019 2018 Included in research and development expenses: Non-cash share-based compensation 1,043,373 561,420 680,541 Included in operating expenses Depreciation - property and equipment 88,957 122,982 95,375 Depreciation - right-of-use assets 357,230 362,592 — Non-cash share-based compensation 1,515,601 908,733 735,292 Transaction cost, warrant derivative — 233,143 — Onerous lease contract — — 67,588 Amortization - lease incentive liability — — 8,189

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of related party [Abstract]
Schedule of related party transactions	2020 2019 2018 Short-term employee compensation and benefits 3,514,527 3,786,667 2,680,621 Termination benefits 495,175 — — Share-based payments 1,757,723 1,123,408 1,067,195 5,767,425 4,910,075 3,747,816

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)	12 Months Ended
	Dec. 31, 2020
Office equipment and furniture
Disclosure of detailed information about property, plant and equipment [line items]
Annual depreciation rate	20.00%
Medical equipment
Disclosure of detailed information about property, plant and equipment [line items]
Annual depreciation rate	20.00%
Computer equipment
Disclosure of detailed information about property, plant and equipment [line items]
Annual depreciation rate	30.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Narrative (Details)	12 Months Ended
	Dec. 31, 2020plan
Summary Of Significant Accounting Policies [Abstract]
Number of plans	1
Maximum option expiration term	10 years

Cash Equivalents - Narrative (D

Cash Equivalents - Narrative (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Equivalents And Short Term Investments [Abstract]
Cash equivalents	$ 30,361,591	$ 13,058,092
Current annual interest rate	0.36%	1.17%

Property and Equipment (Details

Property and Equipment (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	$ 296,768
Property and equipment (amortization), ending balance	236,664	$ 296,768
Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	1,264,367	1,257,353
Additions	28,853	7,014
Disposals	15,137	0
Property and equipment (amortization), ending balance	1,278,083	1,264,367
Amortization
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	(967,599)	(844,617)
Disposals	(15,137)	0
Depreciation expense	88,957	122,982
Property and equipment (amortization), ending balance	(1,041,419)	(967,599)
Medical equipment
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	15,670
Property and equipment (amortization), ending balance	13,862	15,670
Medical equipment | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	60,378	60,378
Additions	1,134	0
Disposals	0	0
Property and equipment (amortization), ending balance	61,512	60,378
Medical equipment | Amortization
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	(44,708)	(24,464)
Disposals	0	0
Depreciation expense	2,942	20,244
Property and equipment (amortization), ending balance	(47,650)	(44,708)
Computer equipment
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	128,909
Property and equipment (amortization), ending balance	116,604	128,909
Computer equipment | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	352,955	345,941
Additions	27,719	7,014
Disposals	15,137	0
Property and equipment (amortization), ending balance	365,537	352,955
Computer equipment | Amortization
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	(224,046)	(174,953)
Disposals	(15,137)	0
Depreciation expense	40,024	49,093
Property and equipment (amortization), ending balance	(248,933)	(224,046)
Office Furniture
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	75,021
Property and equipment (amortization), ending balance	67,033	75,021
Office Furniture | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	247,438	247,438
Additions	0	0
Disposals	0	0
Property and equipment (amortization), ending balance	247,438	247,438
Office Furniture | Amortization
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	(172,417)	(157,749)
Disposals	0	0
Depreciation expense	7,988	14,668
Property and equipment (amortization), ending balance	(180,405)	(172,417)
Office Equipment
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	27,059
Property and equipment (amortization), ending balance	22,739	27,059
Office Equipment | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	105,229	105,229
Additions	0	0
Disposals	0	0
Property and equipment (amortization), ending balance	105,229	105,229
Office Equipment | Amortization
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	(78,170)	(72,828)
Disposals	0	0
Depreciation expense	4,320	5,342
Property and equipment (amortization), ending balance	(82,490)	(78,170)
Leasehold Improvements
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	50,109
Property and equipment (amortization), ending balance	16,426	50,109
Leasehold Improvements | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	498,367	498,367
Additions	0	0
Disposals	0	0
Property and equipment (amortization), ending balance	498,367	498,367
Leasehold Improvements | Amortization
Reconciliation of changes in property, plant and equipment [abstract]
Property and equipment (amortization), beginning balance	(448,258)	(414,623)
Disposals	0	0
Depreciation expense	33,683	33,635
Property and equipment (amortization), ending balance	$ (481,941)	$ (448,258)

Leases - Narrative (Details)

Leases - Narrative (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)renewal	Dec. 31, 2020USD ($)renewal	Dec. 31, 2019CAD ($)	Dec. 31, 2018CAD ($)
Disclosure of quantitative information about right-of-use assets [line items]
Weighted average rate	15.00%	15.00%
Right-of-use assets	$ 372,468	$ 297,373	$ 430,713	$ 808,025
Number of extension options	1	1
Minimum
Disclosure of quantitative information about right-of-use assets [line items]
Lease term	3 years
Maximum
Disclosure of quantitative information about right-of-use assets [line items]
Lease term	5 years

Leases - Right-of-use Assets an

Leases - Right-of-use Assets and Lease Liabilities (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019CAD ($)	Dec. 31, 2018CAD ($)
Presentation of leases for lessee [abstract]
Right-of-use assets, beginning balance	$ 430,713		$ 808,025
Depreciation expense	(357,230)		(362,592)	$ 0
Foreign exchange impact	1,612		(14,720)
Right-of-use assets, ending balance	372,468	$ 297,373	430,713	808,025
Additions to right-of-use assets		297,373
Lease liabilities, beginning balance	506,275		882,437
Additions		$ 297,373
Payment of lease liabilities	(460,724)		(447,497)	0
Interest expense on lease liabilities	68,526		94,817	0
Foreign exchange impact	(9,391)		(23,482)
Lease liabilities, ending balance	$ 402,059		$ 506,275	$ 882,437

Leases - Total Undiscounted Lea

Leases - Total Undiscounted Lease Liability (Details)	Dec. 31, 2020CAD ($)
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease liability	$ 458,512
Less than one year
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease liability	286,509
One to five years
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease liability	172,003
More than five years
Disclosure of maturity analysis of operating lease payments [line items]
Total undiscounted lease liability	$ 0

Warrant Derivative - Narrative

Warrant Derivative - Narrative (Details) - USD ($)	Aug. 16, 2019	Dec. 31, 2020	Dec. 31, 2019
Disclosure of fair value measurement of liabilities [line items]
Gross proceeds from warrant exercises		$ 1,276,532	$ 2,642,082
Shares Under Warrant Derivative Agreement
Disclosure of fair value measurement of liabilities [line items]
Issued (shares)	4,619,773
Purchase price (cad and usd per share)	$ 0.81
Gross proceeds from common shares	$ 3,742,016
Number of common shares issuable per warrant (shares)	1
Warrants | Shares Under Warrant Derivative Agreement
Disclosure of fair value measurement of liabilities [line items]
Purchase price (cad and usd per share)	$ 0.27
Common shares per unit (shares)	1
Exercise price (usd per share)	$ 0.90
Exercise price (usd per share)	0.90
Shares | Shares Under Warrant Derivative Agreement
Disclosure of fair value measurement of liabilities [line items]
Issued (shares)		1,418,369	2,935,647
Purchase price (cad and usd per share)	$ 0.54
Common shares per unit (shares)	1

Warrant Derivative - Reconcilia

Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details) - CAD ($)	4 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Fair Value of Warrant Derivative $
Issued, beginning balance		$ 3,617,570	$ 3,617,570	$ 3,617,900
Change in fair value		3,491,928	(12,608,808)	0
Foreign exchange impact		(9,391)	(23,482)
Issued, ending balance	$ 3,617,570	$ 3,617,570	$ 3,617,570	$ 3,617,570
Warrants
Number of Warrants Outstanding
Issued, beginning balance (shares)	4,619,773	1,684,126
Exercised (shares)		(1,418,369)	(2,935,647)
Issued, ending balance (shares)	1,684,126	265,757	1,684,126
Fair Value of Warrant Derivative $
Issued, beginning balance	$ 1,657,214	$ 8,508,764
Exercised		(4,636,317)	$ (5,687,003)
Change in fair value	12,608,808	(3,491,928)
Foreign exchange impact	(70,255)	150,709
Issued, ending balance	$ 8,508,764	$ 531,228	$ 8,508,764

Warrant Derivative - Summary of

Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)	12 Months Ended
	Dec. 31, 2020year$ / shares	Dec. 31, 2019year$ / shares	Dec. 31, 2018year
Disclosure of fair value measurement of liabilities [line items]
Risk-free interest rate	0.34%	1.62%	2.02%
Expected hold period to exercise | year	3	3	3
Expected share price volatility	110.82%	97.90%	81.15%
Warrants
Disclosure of fair value measurement of liabilities [line items]
Fair value per warrant (usd per share) | $ / shares	$ 1.57	$ 3.89
Underlying share price (usd per share) | $ / shares	$ 2.38	$ 4.76
Risk-free interest rate	0.10%	1.59%
Expected hold period to exercise | year	1	1
Expected share price volatility	90.00%	90.00%
Expected dividend yield	0.00%	0.00%
Dividend Yield, Percent	0.00%	0.00%

Share Capital - Share Consolida

Share Capital - Share Consolidation Narrative (Details)	May 22, 2018shares
Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]
Number of pre-consolidation shares called by post-consolidation shares (in shares)	9.5
Number of post-consolidation shares for each pre-consolidation share (in shares)	1
Stock conversion ratio	0.105263157894737

Share Capital - Schedule of Sha

Share Capital - Schedule of Share Capital (Details) - CAD ($)	Aug. 16, 2019	Jun. 05, 2018	Jun. 01, 2017	May 21, 2018	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of classes of share capital [line items]
Share capital issued, beginning (shares)						32,198,453
Share capital issued ending (shares)							32,198,453
Equity					$ 6,195,363	$ 24,752,993	$ (107,894)	$ 6,195,363
Share issue costs						(1,741,640)	(854,256)	(2,366,809)
Equity				$ 8,283,846		(107,894)	6,195,363	8,283,846
At-the-market agreement
Disclosure of classes of share capital [line items]
Issued shares						$ 40,037,786	8,476,454	620,010
Public Offering
Disclosure of classes of share capital [line items]
Issued (shares)		1,532,278
Issued shares							$ 3,314,429	$ 11,606,882
Share issue costs		$ (1,418,356)
Warrant Derivatives
Disclosure of classes of share capital [line items]
Issued (shares)	4,619,773
Share issue costs	$ (699,427)
Equity Warrants
Disclosure of classes of share capital [line items]
Issued (shares)			16,445,000
Shares
Disclosure of classes of share capital [line items]
Share capital issued, beginning (shares)					14,988,995	32,198,453	17,399,749
Share capital issued ending (shares)					17,399,749	46,166,980	32,198,453	17,399,749
Equity					$ 285,193,061	$ 356,824,172	$ 311,077,859	$ 285,193,061
Share issue costs					(2,333,474)	(1,741,640)	(854,256)
Equity					$ 272,268,722	$ 311,077,859	$ 285,193,061
Shares | Incentive award plan
Disclosure of classes of share capital [line items]
Issued (shares)					28,297	234,172	323,301
Issued shares					$ 109,751	$ 732,367	$ 391,917
Shares | Common Stock Purchase Agreement
Disclosure of classes of share capital [line items]
Issued (shares)					797,691		2,494,943
Issued shares					$ 3,314,097		$ 5,403,385
Shares | At-the-market agreement
Disclosure of classes of share capital [line items]
Issued (shares)					18,002	12,182,532	4,425,040
Issued shares					$ 66,360	$ 40,037,786	$ 8,476,454
Shares | Stock option plan
Disclosure of classes of share capital [line items]
Issued (shares)					34,329	133,454
Issued shares					$ 158,976	$ 385,022
Shares | Public Offering
Disclosure of classes of share capital [line items]
Issued (shares)					1,532,278		4,619,773
Issued shares					$ 11,606,882		$ 3,314,429
Shares | Warrant Derivatives
Disclosure of classes of share capital [line items]
Issued (shares)						1,418,369	2,935,647
Issued shares						$ 6,332,778	$ 9,152,869
Shares | Equity Warrants
Disclosure of classes of share capital [line items]
Issued (shares)					157
Issued shares					$ 1,747
Pre-Consolidation | Shares
Disclosure of classes of share capital [line items]
Share capital issued, beginning (shares)				141,805,722				141,805,722
Share capital issued ending (shares)				142,396,222
Equity				$ 272,268,722
Share issue costs				(33,335)
Equity				$ 271,710,138				$ 271,710,138
Pre-Consolidation | Shares | At-the-market agreement
Disclosure of classes of share capital [line items]
Issued (shares)				519,500
Issued shares				$ 553,650
Pre-Consolidation | Shares | Stock option plan
Disclosure of classes of share capital [line items]
Issued (shares)				71,000
Issued shares				$ 38,269

Share Capital - Schedule of S_2

Share Capital - Schedule of Share Capital Footnotes (Details)	Jun. 15, 2020USD ($)	Aug. 16, 2019CAD ($)shares	Aug. 16, 2019USD ($)$ / sharesshares	Oct. 24, 2018USD ($)	Sep. 27, 2018USD ($)$ / shares	Jun. 05, 2018CAD ($)shares	Jun. 05, 2018USD ($)$ / sharesshares	May 21, 2018CAD ($)	Dec. 31, 2018CAD ($)shares	Dec. 31, 2020CAD ($)shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019CAD ($)shares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018CAD ($)shares	Dec. 31, 2018USD ($)$ / sharesshares	Feb. 25, 2016USD ($)
Disclosure of classes of share capital [line items]
Share issue related cost										$ 1,741,640		$ 854,256		$ 2,366,809
Net proceeds from issue of ordinary shares															$ 48,545
Gross proceeds from warrant exercises											$ 1,276,532		$ 2,642,082
Shares
Disclosure of classes of share capital [line items]
Share issue related cost									$ 2,333,474	$ 1,741,640		$ 854,256
Pre-Consolidation | Shares
Disclosure of classes of share capital [line items]
Share issue related cost								$ 33,335
Canadian ATM
Disclosure of classes of share capital [line items]
Agreement																$ 4,600,000
Issued (shares) | shares														54,684	54,684
Canadian ATM | Pre-Consolidation
Disclosure of classes of share capital [line items]
Issued (shares) | shares														519,500	519,500
Canadian ATM | Pre-Consolidation | Shares
Disclosure of classes of share capital [line items]
Gross proceeds from common shares														$ 553,650
Share issue related cost														$ 33,335
Public Offering
Disclosure of classes of share capital [line items]
Issued (shares) | shares						1,532,278	1,532,278
Gross proceeds from common shares							$ 8,933,181
Share issue related cost						$ 1,418,356
Purchase price (cad and usd per share) | $ / shares							$ 5.83
Public Offering | Shares
Disclosure of classes of share capital [line items]
Issued (shares) | shares									1,532,278			4,619,773	4,619,773
United States ATM
Disclosure of classes of share capital [line items]
Agreement				$ 30,000,000
Issued (shares) | shares										6,741,518	6,741,518	4,425,040	4,425,040	18,002	18,002
Gross proceeds from common shares											$ 17,538,342		$ 6,390,691		$ 50,046
Share issue related cost										$ 856,754		$ 344,834		$ 135,000
Purchase price (cad and usd per share) | $ / shares											$ 2.42		$ 1.70		$ 2.85
Agreement term				19 months
Share issue related cost, commissions											$ 526,150		$ 191,721		$ 1,501
Net proceeds from issue of ordinary shares											$ 17,012,192		$ 6,198,970
2020 United States ATM
Disclosure of classes of share capital [line items]
Agreement	$ 40,000,000
Issued (shares) | shares										5,441,014	5,441,014
Gross proceeds from common shares											$ 12,628,775
Share issue related cost										$ 884,886
Purchase price (cad and usd per share) | $ / shares											$ 2.11
Agreement term	25 months
Share issue related cost, commissions											$ 378,863
Net proceeds from issue of ordinary shares											$ 12,249,911
Common Stock Purchase Agreement
Disclosure of classes of share capital [line items]
Agreement					$ 26,000,000
Agreement term					30 months
Immediately preceding trading days					5 days
Common Stock Purchase Agreement | Shares
Disclosure of classes of share capital [line items]
Issued (shares) | shares									797,691			2,494,943	2,494,943
Common Stock Purchase Agreement | Commitment Shares
Disclosure of classes of share capital [line items]
Issued (shares) | shares										0	0	17,278	17,278	119,509	119,509
Share issue related cost											$ 0		$ 29,758		$ 483,690
Payments for share issue costs										$ 0		$ 3,757		$ 208,726
Common Stock Purchase Agreement | Issued Capital, Excluding Commitment Shares
Disclosure of classes of share capital [line items]
Issued (shares) | shares										0	0	2,477,665	2,477,665	678,182	678,182
Gross proceeds from common shares											$ 0		$ 4,055,725		$ 2,055,207
Warrant Derivatives
Disclosure of classes of share capital [line items]
Issued (shares) | shares		4,619,773	4,619,773
Gross proceeds from common shares			$ 3,742,016
Share issue related cost		$ 699,427
Purchase price (cad and usd per share) | $ / shares			$ 0.81
Number of common shares issuable per warrant (shares) | shares			1
Warrant Derivatives | Included in operating expenses
Disclosure of classes of share capital [line items]
Share issue related cost		233,143
Warrant Derivatives | Shares
Disclosure of classes of share capital [line items]
Issued (shares) | shares										1,418,369	1,418,369	2,935,647	2,935,647
Purchase price (cad and usd per share) | $ / shares			$ 0.54
Common shares per unit (shares) | shares			1
Minimum | Common Stock Purchase Agreement | Shares
Disclosure of classes of share capital [line items]
Purchase price (cad and usd per share) | $ / shares					$ 1
Maximum | Common Stock Purchase Agreement
Disclosure of classes of share capital [line items]
Shares outstanding, percent					19.99%
Warrants
Disclosure of classes of share capital [line items]
Warrants exercised										$ 4,636,317		$ 5,687,003
Warrants exercised (shares) | shares										1,418,369	1,418,369	2,935,647	2,935,647
Warrants | Warrant Derivatives
Disclosure of classes of share capital [line items]
Share issue related cost		$ 466,284
Purchase price (cad and usd per share) | $ / shares			$ 0.27
Common shares per unit (shares) | shares			1
Exercise price (usd per share) | $ / shares			$ 0.90

Share Capital - Summary of Outs

Share Capital - Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)shares	Dec. 31, 2019CAD ($)shares	Dec. 31, 2018CAD ($)shares	Dec. 31, 2018USD ($)shares
Disclosure of classes of share capital [line items]
Issued, beginning balance | $	$ 3,617,570	$ 3,617,570	$ 3,617,900
Issued pursuant to warrant agreement	6,332,778	9,152,869	1,417	$ (330)
Issued, ending balance | $	$ 3,617,570	$ 3,617,570	$ 3,617,570
Warrants exercisable into common shares (shares)	1,730,894
Warrants
Disclosure of classes of share capital [line items]
Number of shares outstanding at beginning of period (shares)	16,443,500	16,443,500	16,445,000	16,445,000
Issued pursuant to equity warrant exercised (shares)			(1,500)	(1,500)
Number of shares outstanding at the end of period (shares)	16,443,500	16,443,500	16,443,500	16,443,500

Share Capital - Equity Warrants

Share Capital - Equity Warrants Narrative (Details) - CAD ($)	Jun. 01, 2017	Dec. 31, 2020
Disclosure of classes of share capital [line items]
Warrants exercisable into common shares (shares)		1,730,894
Shares Public Offering, Equity Warrants
Disclosure of classes of share capital [line items]
Issued (shares)	16,445,000
Gross proceeds from common shares	$ 11,511,500
Common shares per unit (shares)	1
Common share purchase warrant per unit (shares)	1
Warrants exercisable into common shares (shares)	9.5
Number of common shares issuable per warrant (shares)	1
Purchase price (cad per share)	$ 9.025

Share Based Payments - Schedule

Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)	12 Months Ended
	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares	Dec. 31, 2018shares$ / shares
Disclosure Of Share-based Payment Arrangements [Abstract]
Outstanding, beginning of the year (shares) | shares	2,246,947	1,249,361	647,156
Granted during the year (shares) | shares	1,817,500	1,020,000	750,467
Forfeited during the year (shares) | shares	(141,418)	(12,839)	(105,338)
Expired during the year (shares) | shares	(25,520)	(9,575)	(1,122)
Exercised during the year (shares) | shares	(133,454)	0	(41,802)
Outstanding, end of the year (shares) | shares	3,764,055	2,246,947	1,249,361
Options exercisable, end of the year (shares) | shares	2,164,551	1,327,845	777,245
Outstanding, beginning of the year (cad per share) | $ / shares	$ 5.31	$ 8.73	$ 13.20
Granted during the year (cad per share) | $ / shares	3.19	1.42	4.97
Forfeited during the year (cad per share) | $ / shares	3.84	11.35	11.67
Expired during the year (cad per share) | $ / shares	62.49	29.07	13.78
Exercised during the year (cad per share) | $ / shares	1.81	0	2.96
Outstanding, beginning of the year (cad per share) | $ / shares	4.08	5.31	8.73
Options exercisable, end of the year (cad per share) | $ / shares	$ 4.84	$ 7.22	$ 11.04

Share Based Payments - Narrativ

Share Based Payments - Narrative (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Non-cash share-based compensation	$ 2,558,974	$ 1,470,153	$ 1,415,833
Restricted share units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years
Performance share units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years
Reserve of share-based payments
Disclosure of terms and conditions of share-based payment arrangement [line items]
Common shares reserved for issuance (shares)	4,616,698
Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year
Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years

Share Based Payments - Schedu_2

Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)	12 Months Ended
	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares	Dec. 31, 2018shares$ / shares	Dec. 31, 2017shares$ / shares
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number Outstanding (shares) | shares	3,764,055	2,246,947	1,249,361	647,156
Weighted Average Remaining Contractual Life (years)	3 years 6 months 10 days
Weighted Average Exercise Price (cad per share)	$ 4.08	$ 5.31	$ 8.73	$ 13.20
Number Exercisable (shares) | shares	2,164,551	1,327,845	777,245
Weighted Average Exercise Price (cad per share)	$ 4.84	$ 7.22	$ 11.04
$0.54 - $1.79
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number Outstanding (shares) | shares	808,333
Weighted Average Remaining Contractual Life (years)	3 years 10 days
Weighted Average Exercise Price (cad per share)	$ 1.39
Number Exercisable (shares) | shares	545,009
Weighted Average Exercise Price (cad per share)	$ 1.37
$0.54 - $1.79 | Minimum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	0.54
$0.54 - $1.79 | Maximum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	$ 1.79
$1.80 - $3.01
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number Outstanding (shares) | shares	459,730
Weighted Average Remaining Contractual Life (years)	4 years 5 months 26 days
Weighted Average Exercise Price (cad per share)	$ 2.66
Number Exercisable (shares) | shares	289,730
Weighted Average Exercise Price (cad per share)	$ 2.68
$1.80 - $3.01 | Minimum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	1.80
$1.80 - $3.01 | Maximum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	$ 3.01
$3.02 - $3.90
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number Outstanding (shares) | shares	1,834,706
Weighted Average Remaining Contractual Life (years)	3 years 10 months 9 days
Weighted Average Exercise Price (cad per share)	$ 3.21
Number Exercisable (shares) | shares	769,696
Weighted Average Exercise Price (cad per share)	$ 3.26
$3.02 - $3.90 | Minimum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	3.02
$3.02 - $3.90 | Maximum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	$ 3.90
$3.91 - $7.41
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number Outstanding (shares) | shares	493,252
Weighted Average Remaining Contractual Life (years)	2 years 8 months 4 days
Weighted Average Exercise Price (cad per share)	$ 6.13
Number Exercisable (shares) | shares	392,082
Weighted Average Exercise Price (cad per share)	$ 6.02
$3.91 - $7.41 | Minimum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	3.91
$3.91 - $7.41 | Maximum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	$ 7.41
$7.42 - $52.63
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number Outstanding (shares) | shares	168,034
Weighted Average Remaining Contractual Life (years)	2 years 3 months 25 days
Weighted Average Exercise Price (cad per share)	$ 24.32
Number Exercisable (shares) | shares	168,034
Weighted Average Exercise Price (cad per share)	$ 24.32
$7.42 - $52.63 | Minimum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	7.42
$7.42 - $52.63 | Maximum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (cad per share)	$ 52.63

Share Based Payments - Disclosu

Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)year	Dec. 31, 2019CAD ($)year	Dec. 31, 2018CAD ($)year
Disclosure Of Share-based Payment Arrangements [Abstract]
Risk-free interest rate	0.34%	1.62%	2.02%
Expected hold period to exercise | year	3	3	3
Expected share price volatility	110.82%	97.90%	81.15%
Expected forfeiture rate	3.67%	3.67%	3.67%
Expected dividend yield	0.00%	0.00%	0.00%
Weighted average fair value of options (cad per share) | $	$ 2.12	$ 0.87	$ 2.67

Share Based Payments - Schedu_3

Share Based Payments - Schedule of Number of Other Equity Instruments (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)shares	Dec. 31, 2019CAD ($)shares	Dec. 31, 2018CAD ($)shares
Restricted share units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, beginning of the year (shares)	209,657	260,755	190,407
Granted during the year (shares)	154,923	270,098	102,855
Forfeited during the year (shares)	0	0	(4,210)
Vested during the year (shares)	(229,962)	(321,196)	(28,297)
Outstanding, end of the year (shares)	134,618	209,657	260,755
Weighted average fair value at measurement date, other equity instruments granted | $	$ 2.41	$ 0.80	$ 3.35
Performance share units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, beginning of the year (shares)	61,051	63,156	94,734
Forfeited during the year (shares)	0	0	(31,578)
Vested during the year (shares)	(4,210)	(2,105)	0
Outstanding, end of the year (shares)	56,841	61,051	63,156

Loss Per Common Share (Details)

Loss Per Common Share (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings per share [abstract]
Weighted average number of common shares outstanding (shares)	40,338,789	22,137,990	16,016,366

Contract Liability and Receiv_3

Contract Liability and Receivable - Narrative (Details)	12 Months Ended
	Dec. 31, 2020year
Disclosure of revenue from contracts with customers [Abstract]
Expected recognition period	5

Contract Liability and Receiv_4

Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019CAD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020CAD ($)	Dec. 31, 2019CAD ($)
Disclosure of revenue from contracts with customers [Abstract]
Balance, beginning of the year	$ 6,730,287	$ 6,730,287		$ 6,730,287
Regional licensing agreement	0		$ 0
Revenue recognized in the year		0		0
Balance, end of the year	6,730,287	6,730,287	6,730,287	6,730,287
Contract liability - current					$ 0	$ 0
Contract liability - non-current					6,730,287	6,730,287
Contract liabilities	$ 6,730,287	$ 6,730,287	$ 6,730,287	$ 6,730,287	$ 6,730,287	$ 6,730,287

Commitments (Details)

Commitments (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019CAD ($)	Dec. 31, 2019USD ($)
Commitments [Abstract]
Commitment for payment	$ 9,360,653
Disclosure of other provisions [line items]
Commitment for payment	$ 9,360,653
Commitment term	2 years
Other liabilities	$ 123,985		$ 847,215
Repayment, maximum	400,000
Overhead repayment	$ 100,000
Annual installment of gross sales of product, percent	5.00%	5.00%
Annual installment of annual product sales	$ 100,000
BRACELET-1 collaboration agreement
Disclosure of other provisions [line items]
Other receivables		$ 0		$ 1,500,000
Other liabilities	$ 97,381		$ 652,306

Contingencies (Details)

Contingencies (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of contingent liabilities [line items]
Royalty payment on sales revenue, percent	0.50%
Royalty payment maximum	$ 20,000
SYNSORB
Disclosure of contingent liabilities [line items]
Milestone payment in connection with Share Purchase Agreement	$ 1,000,000
Payment due period	90 days
Royalty payment due to founding shareholders, percent	10.75%	10.75%
Royalty payment on net sales due to founding shareholders, percent	2.15%	2.15%

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of income tax [Abstract]
Loss before income taxes	$ (22,505,057)	$ (33,122,888)	$ (16,489,183)
Statutory Canadian corporate tax rate	24.00%	26.50%	27.00%
Anticipated tax recovery	$ (5,401,214)	$ (8,777,565)	$ (4,452,079)
Foreign jurisdiction tax rate difference	3,237,898	3,088,811	3,312,963
Employee share-based compensation	614,154	389,591	382,275
Change in fair value of warrant derivative	(838,063)	3,341,334	0
Impact of Alberta rate change	96,028	3,758,175	0
Adjustment to opening tax pools	20,711	11,973	(238,222)
Other permanent differences	108,945	149,294	(35,912)
Change in deferred tax benefits deemed not probable to be recovered	2,161,541	(1,961,613)	1,579,017
Current income taxes	0	0	548,042
Adjustment in respect to prior periods	0	0	0
Net current tax expense	$ 0	$ 0	$ 548,042

Income Taxes - Summary of Non-c

Income Taxes - Summary of Non-capital Losses (Details) - Non-capital losses $ in Thousands	Dec. 31, 2020CAD ($)
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	$ 78,994
2026
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	9,809
2027
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	12,170
2029
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	4,009
2030
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	4,774
2031
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	4,343
2032
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	2,873
2033
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	2,457
2034
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	2,472
2035
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	3,125
2036
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	6,430
2037
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	4,812
2038
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	5,056
2039
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	6,864
2040
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax losses	$ 9,800

Income Taxes - Summary of Non-r

Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)	Dec. 31, 2020CAD ($)
Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	$ 5,304,980
Unclaimed scientific research and experimental development expenditures
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	27,660,000
2021 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	471,000
2022 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	465,000
2023 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	361,000
2024 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	228,000
2025 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	271,000
2026 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	520,000
2027 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	596,000
2028 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	622,000
2029 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	173,000
2030 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	91,000
2031 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	114,000
2032 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	381,000
2033 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	487,000
2034 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	270,000
2035 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	183,000
2036 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	41,000
2037 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	980
2038 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	22,000
2039 | Non-refundable federal investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits	$ 8,000

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details) - CAD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax asset	$ 34,541,435	$ 32,712,066	$ 34,712,675
Net operating losses carried forward
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax asset	21,487,804	19,625,642	20,664,345
Scientific research and experimental development
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax asset	6,362,152	6,338,542	7,406,169
Investment tax credits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax asset	4,068,105	4,222,016	3,988,606
Undepreciated capital costs in excess of book value of property and equipment and intellectual property
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax asset	1,927,709	1,908,320	1,949,611
Share issue costs
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax asset	689,193	611,072	696,346
Net capital losses carried forward
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax asset	$ 6,472	$ 6,474	$ 7,598

Capital Disclosures (Details)

Capital Disclosures (Details) - CAD ($)	Dec. 31, 2020	Jun. 12, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of changes in equity [abstract]
Cash and cash equivalents	$ 31,219,574		$ 14,148,021	$ 13,699,881	$ 11,836,119
Shareholders’ equity (deficit)	$ 24,752,993		$ (107,894)	$ 6,195,363	$ 8,283,846
Base Shelf securities authorized		$ 150,000,000

Financial Instruments - Narrati

Financial Instruments - Narrative (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020GBP (£)	Dec. 31, 2020EUR (€)	Dec. 31, 2019CAD ($)
Disclosure of nature and extent of risks arising from financial instruments [line items]
Warrant derivative	$ 531,228				$ 8,508,764
U.S. dollars
Disclosure of nature and extent of risks arising from financial instruments [line items]
Warrant derivative		$ 417,238
British pounds
Disclosure of nature and extent of risks arising from financial instruments [line items]
Warrant derivative | £			£ 0
Euro
Disclosure of nature and extent of risks arising from financial instruments [line items]
Warrant derivative | €				€ 0
Currency risk | U.S. dollars
Disclosure of nature and extent of risks arising from financial instruments [line items]
Impact of increase in value of currency, amount	0.01
(Increase) decrease in net loss due to change in currency value	172,000
Impact of increase in value of currency, amount	0.01
Currency risk | British pounds
Disclosure of nature and extent of risks arising from financial instruments [line items]
Impact of increase in value of currency, amount	0.10
(Increase) decrease in net loss due to change in currency value	(20,000)
Impact of increase in value of currency, amount	0.10
Currency risk | Euro
Disclosure of nature and extent of risks arising from financial instruments [line items]
Impact of increase in value of currency, amount	0.10
(Increase) decrease in net loss due to change in currency value	(3,000)
Impact of increase in value of currency, amount	0.10
Level 2
Disclosure of nature and extent of risks arising from financial instruments [line items]
Warrant derivative	$ 531,228				$ 8,508,764

Financial Instruments - Schedul

Financial Instruments - Schedule of Balances in Foreign Currencies (Details)	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020GBP (£)	Dec. 31, 2020EUR (€)	Dec. 31, 2019CAD ($)	Dec. 31, 2018CAD ($)	Dec. 31, 2017CAD ($)
Currency1 [Line Items]
Cash and cash equivalents	$ 31,219,574				$ 14,148,021	$ 13,699,881	$ 11,836,119
Accounts payable and accrued liabilities	(1,805,015)				(3,173,218)
Warrant derivative	$ (531,228)				$ (8,508,764)
U.S. dollars
Currency1 [Line Items]
Cash and cash equivalents		$ 23,134,113
Accounts payable and accrued liabilities		(455,588)
Warrant derivative		(417,238)
Balances in foreign currencies		$ 22,261,287
British pounds
Currency1 [Line Items]
Cash and cash equivalents | £			£ 26,768
Accounts payable and accrued liabilities | £			(2,244)
Warrant derivative | £			0
Balances in foreign currencies | £			£ 24,524
Euro
Currency1 [Line Items]
Cash and cash equivalents | €				€ 37,347
Accounts payable and accrued liabilities | €				(930)
Warrant derivative | €				0
Balances in foreign currencies | €				€ 36,417

Additional Cash Flow Disclosu_3

Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of cash flows [abstract]
Contract receivable	$ 0	$ 0	$ 4,767,100
Other receivables	1,979,111	(2,017,122)	(13,924)
Prepaid expenses	286,391	(2,012,605)	475,077
Accounts payable and accrued liabilities	(1,368,203)	1,347,365	(1,858,170)
Contract liability	0	0	547,707
Other liabilities	(723,230)	807,877	(27,982)
Non-cash impact of foreign exchange	35,710	78,708	14,531
Change in non-cash working capital related to operating activities	$ 209,779	$ (1,795,777)	$ 3,904,339

Additional Cash Flow Disclosu_4

Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of cash flows [abstract]
Cash interest received	$ 189,720	$ 274,094	$ 173,496
Cash taxes paid	$ 12,080	$ 5,448	$ 15,728

Economic Dependence (Details)

Economic Dependence (Details)	12 Months Ended
	Dec. 31, 2020manufacturer
Toll manufacturer
Concentration Risk Type1 [Line Items]
Concentration, number	1

Other Expenses and Adjustment_2

Other Expenses and Adjustments (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019CAD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018CAD ($)	Dec. 31, 2018USD ($)
Other Expenses And Adjustments [Line Items]
Non-cash share-based compensation	$ 2,558,974		$ 1,470,153		$ 1,415,833
Depreciation - right-of-use assets	357,230		362,592		0
Transaction cost, warrant derivative	1,741,640		854,256		2,366,809
Onerous lease contract	0		0		67,588
Amortization - lease incentive liability	0		0		8,189
Included in research and development expenses:
Other Expenses And Adjustments [Line Items]
Non-cash share-based compensation	1,043,373		561,420		680,541
Included in operating expenses
Other Expenses And Adjustments [Line Items]
Non-cash share-based compensation	1,515,601		908,733		735,292
Depreciation - property and equipment	88,957		122,982		95,375
Depreciation - right-of-use assets		$ 357,230		$ 362,592		$ 0
Onerous lease contract	0		0		67,588
Amortization - lease incentive liability	0		0		8,189
Included in operating expenses | Warrants
Other Expenses And Adjustments [Line Items]
Transaction cost, warrant derivative	$ 0		$ 233,143		$ 0

Related Party Transactions (Det

Related Party Transactions (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of related party [Abstract]
Short-term employee compensation and benefits	$ 3,514,527	$ 3,786,667	$ 2,680,621
Termination benefits	495,175	0	0
Share-based payments	1,757,723	1,123,408	1,067,195
Compensation of key management personnel	$ 5,767,425	$ 4,910,075	$ 3,747,816

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	2 Months Ended	12 Months Ended
	Mar. 04, 2021	Dec. 31, 2020	Dec. 31, 2018
Disclosure of non-adjusting events after reporting period [line items]
Net proceeds from issue of ordinary shares			$ 48,545
2020 United States ATM
Disclosure of non-adjusting events after reporting period [line items]
Issued (shares)		5,441,014
Gross proceeds from common shares		$ 12,628,775
Purchase price (cad and usd per share)		$ 2.11
Share issue related cost, commissions		$ 378,863
Net proceeds from issue of ordinary shares		$ 12,249,911
Share transactions | 2020 United States ATM
Disclosure of non-adjusting events after reporting period [line items]
Issued (shares)	5,685,097
Gross proceeds from common shares	$ 18,503,188
Purchase price (cad and usd per share)	$ 2.85
Share issue related cost, commissions	$ 555,096
Net proceeds from issue of ordinary shares	$ 17,948,092